Last edition
Aurobindo Pharma's API Facility Receives Zero Observations in US FDA Inspection
Aurobindo Pharma has announced that the US Food and Drug Administration (FDA) completed an inspection of Unit-4, an Active Pharmaceutical Ingredient (API) manufacturing facility of its wholly owned subsidiary, Apitoria Pharma, in Andhra Pradesh.
The inspection was conducted from September 7 to September 11, 2026, at the facility located in the Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam district.
According to Aurobindo Pharma, the inspection concluded with zero observations.
The company said it remains committed to maintaining quality and compliance standards across its manufacturing facilities.
Active Pharmaceutical Ingredient Aurobindo Pharma FDA inspection of Unit-4 Food and Drug Administration Industrial Development Area US FDA Wholly owned subsidiary Zero observations
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy